Mutant islet amyloid polypeptides with improved solubility and methods for using the same
AssigneeThe Research Foundation for The State University of New York
InventorsDaniel Raleigh, Rehana Akter, Andisheh Abedini
Life of this patent
Estimating the term…
Abstract
Isolated non-naturally occurring, mutant-human islet amyloid polypeptides (IAPP) polypeptides, which are more soluble at neutral pH than the wild-type human islet amyloid polypeptide (hIAPP) protein are disclosed. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides to be delivered to a subject in a single injection with an insulin agent. Methods and pharmacological compositions for treating an abnormal condition, such as an amyloid-based disease or type-1 diabetes in a subject are also disclosed.
Claims19
An isolated mutant-human islet amyloid polypeptide hIAPP comprising an amino acid sequence that comprises at least two amino acid substitutions relative to the wild-type hIAPP polypeptide set forth in SEQ ID NO:
- 1 at positions 21, 22, 31 and 35, wherein said at least two amino acid substitutions comprise a substitution with lysine or arginine.
Dependencies are inferred from the claim text.